{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:47:23Z","timestamp":1793713643326,"version":"4.6.1"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.metabol.2021.154890","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T02:06:44Z","timestamp":1632276404000},"page":"154890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":187,"special_numbering":"C","title":["Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies"],"prefix":"10.1016","volume":"124","author":[{"given":"Carlo Alberto","family":"Ricciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gnudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154890_bb0005","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s001250100000","article-title":"Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy","volume":"44","author":"Cooper","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0010","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1681\/ASN.2006121362","article-title":"Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism","volume":"18","author":"Gnudi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0015","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1042\/CS20150403","article-title":"Vascular growth factors play critical roles in kidney glomeruli","volume":"129","author":"Gnudi","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154890_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.freeradbiomed.2017.12.040","article-title":"Diabetic nephropathy: is there a role for oxidative stress?","volume":"116","author":"Sagoo","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0030","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/diabetes.49.11.1939","article-title":"High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C\u2014dependent activation of NAD(P)H oxidase in cultured vascular cells","volume":"49","author":"Inoguchi","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/labinvest.2015.128","article-title":"Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic mice","volume":"96","author":"Nagasu","year":"2016","journal-title":"Lab Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1042\/CS20160846","article-title":"The emerging role of NADPH oxidase NOX5 in vascular disease","volume":"131","author":"Jha","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154890_bb0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00125-015-3796-0","article-title":"Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy","volume":"59","author":"Jha","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0050","doi-asserted-by":"crossref","first-page":"39616","DOI":"10.1074\/jbc.M502412200","article-title":"Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney","volume":"280","author":"Gorin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154890_bb0055","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2337\/db16-1585","article-title":"NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy","volume":"66","author":"Jha","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0060","doi-asserted-by":"crossref","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","article-title":"Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes","volume":"308","author":"Gorin","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0065","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/db08-0057","article-title":"Oxidative stress as a major culprit in kidney disease in diabetes","volume":"57","author":"Forbes","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0070","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/db14-0874","article-title":"Mitochondrial hormesis and diabetic complications","volume":"64","author":"Sharma","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0075","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1172\/JCI66218","article-title":"AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function","volume":"123","author":"Dugan","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ebiom.2015.04.002","article-title":"Altered mitochondrial function, mitochondrial DNA and reduced metabolic flexibility in patients with diabetic nephropathy","volume":"2","author":"Czajka","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.metabol.2021.154890_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.redox.2015.12.008","article-title":"The Bioenergetic Health Index is a sensitive measure of oxidative stress in human monocytes","volume":"8","author":"Chacko","year":"2015","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2021.154890_bb0095","doi-asserted-by":"crossref","first-page":"37503","DOI":"10.1074\/jbc.M110.136796","article-title":"AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes","volume":"285","author":"Eid","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154890_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000381190","article-title":"Renoprotective effects of fenofibrate via modulation of LKB1\/AMPK mRNA expression and endothelial dysfunction in a rat model of diabetic nephropathy","volume":"95","author":"Al-Rasheed","year":"2015","journal-title":"Pharmacology"},{"key":"10.1016\/j.metabol.2021.154890_bb0105","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2337\/db12-1504","article-title":"Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury","volume":"62","author":"Eid","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2021.154890_bb0115","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"Godel","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2337\/db11-0555","article-title":"Nutrient sensing, autophagy, and diabetic nephropathy","volume":"61","author":"Kume","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10157-013-0880-y","article-title":"Abnormal lipoprotein metabolism in diabetic nephropathy","volume":"18","author":"Hirano","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0130","article-title":"The role of cholesterol homeostasis in diabetic kidney disease","author":"Chen","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.metabol.2021.154890_bb0135","article-title":"Endoplasmic reticulum stress in chronic kidney disease. New molecular targets from bench to the bedside","volume":"36","author":"Ricciardi","year":"2019","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/jcm4040715","article-title":"Endoplasmic reticulum stress in the diabetic kidney, the good, the bad and the ugly","volume":"4","author":"Cunard","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0145","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1440-1681.1997.tb01241.x","article-title":"Contractile properties of afferent and efferent arterioles","volume":"24","author":"Ito","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0150","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1681\/ASN.2020040423","article-title":"Tubuloglomerular feedback synchronization in nephrovascular networks","volume":"32","author":"Zehra","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ki.1981.33","article-title":"Glomerular hemodynamics in experimental diabetes mellitus","volume":"19","author":"Hostetter","year":"1981","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154890_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0002-9343(82)90490-9","article-title":"The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. [Review] [49 refs]","volume":"72","author":"Hostetter","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1523-1755.2001.00787.x","article-title":"Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide","volume":"60","author":"De Vriese","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154890_bb0170","doi-asserted-by":"crossref","first-page":"F1069","DOI":"10.1152\/ajprenal.00345.2004","article-title":"TGF-beta impairs renal autoregulation via generation of ROS","volume":"288","author":"Sharma","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0175","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1016\/j.amjhyper.2004.11.040","article-title":"The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease","volume":"18","author":"Raij","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.metabol.2021.154890_bb0180","series-title":"The kidney","first-page":"319","article-title":"Glomerular ultrafiltration","author":"Maddox","year":"2000"},{"key":"10.1016\/j.metabol.2021.154890_bb0185","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0195","series-title":"Oxford textbook of clinical nephrology","first-page":"1199","article-title":"The patient with diabetes mellitus","author":"Gnudi","year":"2016"},{"key":"10.1016\/j.metabol.2021.154890_bb0200","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/db07-1149","article-title":"RhoA\/rho-kinase contribute to the pathogenesis of diabetic renal disease","volume":"57","author":"Peng","year":"2008","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2021.154890_bb0205","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.ASN.0000093460.24823.5B","article-title":"Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator","volume":"15","author":"Ziyadeh","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/01.ASN.0000065640.77499.D7","article-title":"Extracellular matrix metabolism in diabetic nephropathy","volume":"14","author":"Mason","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonzalez","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000101797","article-title":"Cellular and molecular mechanisms of proteinuria in diabetic nephropathy","volume":"106","author":"Wolf","year":"2007","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0225","doi-asserted-by":"crossref","first-page":"F697","DOI":"10.1152\/ajprenal.00016.2008","article-title":"MCP-1\/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy","volume":"294","author":"Tesch","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.HYP.0000075949.19968.EF","article-title":"GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury?","volume":"42","author":"Gnudi","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2021.154890_bb0235","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00125-008-0961-8","article-title":"What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?","volume":"51","author":"Satchell","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0240","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1152\/physrev.00055.2006","article-title":"Properties of the glomerular barrier and mechanisms of proteinuria","volume":"88","author":"Haraldsson","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2021.154890_bb0245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1172\/JCI119163","article-title":"Podocyte loss and progressive glomerular injury in type II diabetes","volume":"99","author":"Pagtalunan","year":"1997","journal-title":"J Clin Investig"},{"key":"10.1016\/j.metabol.2021.154890_bb0250","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.2337\/diabetes.54.11.3095","article-title":"The human glomerular podocyte is a novel target for insulin action","volume":"54","author":"Coward","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0255","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cmet.2010.08.015","article-title":"Insulin signaling to the glomerular podocyte is critical for normal kidney function","volume":"12","author":"Welsh","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2021.154890_bb0260","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0265","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00125-010-2034-z","article-title":"Podocyte vascular endothelial growth factor (Vegf) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes","volume":"54","author":"Veron","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0270","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.2337\/db08-0647","article-title":"Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice","volume":"57","author":"Ku","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0275","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1681\/ASN.V125993","article-title":"Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes","volume":"12","author":"De Vriese","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0280","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.metabol.2021.154890_bb0285","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.metabol.2012.04.004","article-title":"VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment?","volume":"61","author":"Dei Cas","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2021.154890_bb0290","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1681\/ASN.V11171","article-title":"Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy","volume":"11","author":"Veelken","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0295","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/db09-0119","article-title":"Abnormal angiogenesis in diabetic nephropathy","volume":"58","author":"Nakagawa","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0300","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.90450.2008","article-title":"Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse","volume":"296","author":"Nakayama","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0305","doi-asserted-by":"crossref","first-page":"590541","DOI":"10.1155\/2014\/590541","article-title":"Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice","volume":"2014","author":"Takahashi","year":"2014","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.metabol.2021.154890_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fmed.2018.00076","article-title":"Glomerular endothelial cells stress and cross-talk with podocytes in the development of diabetic kidney disease","volume":"5","author":"Daehn","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0315","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2011121170","article-title":"eNOS deficiency predisposes podocytes to injury in diabetes","volume":"23","author":"Yuen","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0320","doi-asserted-by":"crossref","first-page":"987064","DOI":"10.1155\/2013\/987064","article-title":"A glimpse of the pathogenetic mechanisms of Wnt\/beta-catenin signaling in diabetic nephropathy","volume":"2013","author":"Xiao","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.metabol.2021.154890_bb0325","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1681\/ASN.2009010019","article-title":"Wnt\/beta-catenin signaling promotes podocyte dysfunction and albuminuria","volume":"20","author":"Dai","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0330","doi-asserted-by":"crossref","first-page":"F1152","DOI":"10.1152\/ajprenal.00373.2010","article-title":"GSK3beta inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility","volume":"300","author":"George","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0335","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/01.RES.0000156273.30274.f7","article-title":"Glycogen-synthase kinase3beta\/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells","volume":"96","author":"Skurk","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2021.154890_bb0340","first-page":"131","article-title":"The role of Wnt signalling in angiogenesis","volume":"38","author":"Olsen","year":"2017","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.metabol.2021.154890_bb0345","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2337\/db19-0157","article-title":"Overexpression of circulating soluble Nogo-B improves diabetic kidney disease by protecting the vasculature","volume":"68","author":"Hernandez-Diaz","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0350","doi-asserted-by":"crossref","first-page":"35363","DOI":"10.1074\/jbc.M114.587840","article-title":"Activation of glycogen synthase kinase 3beta ameliorates diabetes-induced kidney injury","volume":"289","author":"Mariappan","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154890_bb0355","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1681\/ASN.2006101093","article-title":"Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia","volume":"18","author":"Davis","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0360","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2004.11.004","article-title":"Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage\/dysfunction and atherosclerosis","volume":"180","author":"Lim","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2021.154890_bb0365","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1172\/JCI46322","article-title":"Angiopoietin-1 is essential in mouse vasculature during development and in response to injury","volume":"121","author":"Jeansson","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.metabol.2021.154890_bb0370","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.2012121218","article-title":"Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease","volume":"25","author":"Dessapt-Baradez","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0375","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1172\/JCI84923","article-title":"Tie1 controls angiopoietin function in vascular remodeling and inflammation","volume":"126","author":"Korhonen","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0380","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1172\/JCI89963","article-title":"Tie1: an orphan receptor provides context for angiopoietin-2\/Tie2 signaling","volume":"126","author":"Mueller","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0385","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tem.2016.07.002","article-title":"Diabetic nephropathy: perspective on novel molecular mechanisms","volume":"27","author":"Gnudi","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154890_bb0390","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1172\/JCI84871","article-title":"Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation","volume":"126","author":"Kim","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0395","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrm3507","article-title":"FOXOs: signalling integrators for homeostasis maintenance","volume":"14","author":"Eijkelenboom","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.metabol.2021.154890_bb0400","doi-asserted-by":"crossref","first-page":"630617","DOI":"10.3389\/fphar.2021.630617","article-title":"Improving the dysregulation of FoxO1 activity is a potential therapy for alleviating diabetic kidney disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2021.154890_bb0405","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbrc.2015.09.024","article-title":"Effects of FoxO1 on podocyte injury in diabetic rats","volume":"466","author":"Guo","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2021.154890_bb0410","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jcb.25249","article-title":"Lentiviral vector-mediated FoxO1 overexpression inhibits extracellular matrix protein secretion under high glucose conditions in mesangial cells","volume":"117","author":"Guo","year":"2016","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.metabol.2021.154890_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2015.06.007","article-title":"Activation of FoxO1\/PGC-1alpha prevents mitochondrial dysfunction and ameliorates mesangial cell injury in diabetic rats","volume":"413","author":"Wu","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.metabol.2021.154890_bb0420","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ebiom.2019.09.002","article-title":"FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease","volume":"48","author":"Huang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.metabol.2021.154890_bb0425","doi-asserted-by":"crossref","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","article-title":"The proximal tubule in the pathophysiology of the diabetic kidney","volume":"300","author":"Vallon","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0430","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1046\/j.1523-1755.1999.00721.x","article-title":"The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?","volume":"56","author":"Gilbert","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154890_bb0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0962-8924(03)00035-7","article-title":"Nogo and its paRTNers","volume":"13","author":"Oertle","year":"2003","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.metabol.2021.154890_bb0440","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2005.11.047","article-title":"A class of membrane proteins shaping the tubular endoplasmic reticulum","volume":"124","author":"Voeltz","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2021.154890_bb0445","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1523\/JNEUROSCI.22-09-03553.2002","article-title":"Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions","volume":"22","author":"Huber","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.metabol.2021.154890_bb0450","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm1020","article-title":"A new role for Nogo as a regulator of vascular remodeling","volume":"10","author":"Acevedo","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0455","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/mt.2008.188","article-title":"In vivo modulation of Nogo-B attenuates neointima formation","volume":"16","author":"Kritz","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.metabol.2021.154890_bb0460","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/15384101.2015.1044187","article-title":"Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN response","volume":"14","author":"Ahn","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.metabol.2021.154890_bb0465","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/ATVBAHA.107.140913","article-title":"Low levels of Nogo-B in human carotid atherosclerotic plaques are associated with an atheromatous phenotype, restenosis, and stenosis severity","volume":"27","author":"Rodriguez-Feo","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154890_bb0470","doi-asserted-by":"crossref","first-page":"10997","DOI":"10.1073\/pnas.0602427103","article-title":"Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells","volume":"103","author":"Miao","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2021.154890_bb0475","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1182\/blood-2010-02-271577","article-title":"Nogo-B receptor is essential for angiogenesis in zebrafish via Akt pathway","volume":"116","author":"Zhao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2021.154890_bb0480","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1681\/ASN.2016091001","article-title":"Inhibition of reticulon-1A-mediated endoplasmic reticulum stress in early AKI attenuates renal fibrosis development","volume":"28","author":"Fan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0485","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US renal data system 2018 annual data report: epidemiology of kidney disease in the United States","volume":"73","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2021.154890_bb0490","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2021.154890_bb0495","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1755.2001.059002702.x","article-title":"Progression of diabetic nephropathy","volume":"59","author":"Hovind","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154890_bb0500","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0505","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ndt\/4.10.859","article-title":"Similar risks of nephropathy in patients with type I or type II diabetes mellitus","volume":"4","author":"Hasslacher","year":"1989","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2021.154890_bb0510","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/diacare.26.8.2392","article-title":"Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans","volume":"26","author":"Young","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0515","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000412","article-title":"Presentation, pathology and prognosis of renal disease in type 2 diabetes","volume":"5","author":"Tan","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0525","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000492633","article-title":"The susceptibility genes in diabetic nephropathy","volume":"4","author":"Wei","year":"2018","journal-title":"Kidney Dis"},{"key":"10.1016\/j.metabol.2021.154890_bb0530","first-page":"206","article-title":"Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease","volume":"31","author":"Karalliedde","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2021.154890_bb0535","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0140-6736(93)90167-F","article-title":"Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria","volume":"341","author":"Yip","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2021.154890_bb0540","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0140-6736(93)91943-G","article-title":"Insulin resistance in insulin-dependent diabetic patients with microalbuminuria","volume":"342","author":"Yip","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2021.154890_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v3.i1.1","article-title":"Renal hyperfiltration related to diabetes mellitus and obesity in human disease","volume":"3","author":"Sasson","year":"2012","journal-title":"World J Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0550","first-page":"1347","article-title":"Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria","volume":"47","author":"Trevisan","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0555","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00125-003-1303-5","article-title":"Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: the role of insulin resistance","volume":"47","author":"Vedovato","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0560","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Group KCW","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.metabol.2021.154890_bb0565","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0570","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1159\/000117461","article-title":"Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis","volume":"28","author":"Jerums","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0575","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2010030250","article-title":"Proteinuria in diabetes: bystander or pathway to cardiorenal disease?","volume":"21","author":"Karalliedde","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0580","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/jcm4091761","article-title":"Non-proteinuric diabetic nephropathy","volume":"4","author":"Robles","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0585","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2337\/diacare.27.1.195","article-title":"Nonalbuminuric renal insufficiency in type 2 diabetes","volume":"27","author":"MacIsaac","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0590","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2021.154890_bb0595","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc08-2186","article-title":"Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11)","volume":"32","author":"Thomas","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0600","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0605","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0610","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00125-017-4251-1","article-title":"Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus","volume":"60","author":"Penno","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0615","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/HJH.0b013e3283495cd6","article-title":"Clinical significance of nonalbuminuric renal impairment in type 2 diabetes","volume":"29","author":"Penno","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2021.154890_bb0620","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2337\/dc05-1788","article-title":"Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?","volume":"29","author":"MacIsaac","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0625","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1159\/000484538","article-title":"Non-diabetic kidney disease in type 2 diabetic patients: prevalence, clinical predictors and outcomes","volume":"42","author":"Erdogmus","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.metabol.2021.154890_bb0630","first-page":"97","article-title":"Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies","volume":"32","author":"Fiorentino","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2021.154890_bb0635","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.metabol.2021.154890_bb0640","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00125-018-4691-2","article-title":"Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study","volume":"61","author":"Penno","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0645","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0650","article-title":"Intercapillary lesions in the glomeruli of the kidney","volume":"12","author":"Kimmelstiel","year":"1936","journal-title":"Am J Pathol"},{"key":"10.1016\/j.metabol.2021.154890_bb0655","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/IJNRD.S37883","article-title":"Tubulointerstitial disease in diabetic nephropathy","volume":"7","author":"Tonolo","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.metabol.2021.154890_bb0660","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0665","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0670","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study","volume":"2","author":"Group DEr","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2021.154890_bb0675","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0680","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2021.154890_bb0685","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2021.154890_bb0690","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0695","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2021.154890_bb0700","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2006080872","article-title":"Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes","volume":"18","author":"Perkins","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0705","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/jcm4050948","article-title":"Hypoglycemia in patients with diabetes and renal disease","volume":"4","author":"Alsahli","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0710","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1111\/j.1523-1755.2005.09415.x","article-title":"Role of lipid control in diabetic nephropathy","author":"Chen","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.metabol.2021.154890_bb0715","doi-asserted-by":"crossref","first-page":"16632","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis","volume":"9","author":"Esmeijer","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2021.154890_bb0720","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2021.154890_bb0725","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.5551\/jat.9084","article-title":"Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy","volume":"18","author":"Abe","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.metabol.2021.154890_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162731","article-title":"Renoprotective effects of atorvastatin in diabetic mice: downregulation of RhoA and upregulation of Akt\/GSK3","volume":"11","author":"Bruder-Nascimento","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2021.154890_bb0735","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2337\/db07-1241","article-title":"Targeting of RhoA\/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control","volume":"57","author":"Kolavennu","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0740","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5301\/jn.5000128","article-title":"Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells","volume":"26","author":"Gao","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0745","doi-asserted-by":"crossref","first-page":"F528","DOI":"10.1152\/ajprenal.00127.2010","article-title":"The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse","volume":"299","author":"Giunti","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2021.154890_bb0750","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/diabetes.47.3.439","article-title":"Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients","volume":"47","author":"Fagerudd","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154890_bb0755","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/BF02374490","article-title":"Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians","volume":"36","author":"Nelson","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154890_bb0760","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/1056-8727(92)90034-I","article-title":"High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus","volume":"6","author":"Haneda","year":"1992","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2021.154890_bb0765","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1046\/j.1464-5491.1999.00182.x","article-title":"Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study","volume":"16","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0770","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0272-6386(99)70036-3","article-title":"Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group","volume":"34","author":"Lewis","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2021.154890_bb0775","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0780","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0785","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154890_bb0790","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0795","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0800","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0805","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0810","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria","volume":"19","author":"Gaede","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2021.154890_bb0815","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0820","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0825","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0830","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0835","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0840","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0845","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0850","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2021.154890_bb0855","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes A","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154890_bb0860","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154890_bb0865","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria","volume":"349","author":"The EUCLID Study Group","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2021.154890_bb0870","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0875","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0880","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0885","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0890","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [see comments]","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0895","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154890_bb0900","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521001906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521001906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:29:41Z","timestamp":1758428981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":180,"alternative-id":["S0026049521001906"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154890","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154890"}}